From: A novel assay for monitoring internalization of nanocarrier coupled antibodies
Chelating lipid | Drug loaded1 | Drug-to-lipid2 ratio – input (μg/μmol) | Drug-to-lipid3 ratio – final (μg/μmol) | Loading4 efficiency (%) |
---|---|---|---|---|
none | DOX | 150 | 159.4 ± 6.1 | 106.3 ± 14.4 |
Ni-NTA-DOGS | DOX | 150 | 40.4 ± 4.3 | 26.9 ± 3.0 |
Ni-NTA-PEG-DSPE | DOX | 150 | 138.2 ± 10.2 | 92.2 ± 8.0 |
none | VRB | 150 | 150.2 ± 4.9 | 100.2 ± 3.4 |
Ni-NTA-DOGS | VRB | 150 | 13.6 ± 1.2 | 9.0 ± 0.9 |
Ni-NTA-PEG-DSPE | VRB | 150 | 149.6 ± 5.8 | 99.8 ± 4.0 |
none | MTX | 508 | 146.0 ± 20.3 | 28.7 ± 4.0 |
Ni-NTA-DOGS | MTX | 508 | 149.8 ± 6.6 | 29.5 ± 1.3 |
Ni-NTA-PEG-DSPE | MTX | 508 | 151.1 ± 7.2 | 29.7 ± 2.0 |